109 results about "Fluoxetine" patented technology

The subject invention provides methods for treating symptoms and/or conditions associated with idiopathic hyperhidrosis by using compounds that decrease the activity of serotonin 5-HT2C receptors. Compounds that can ameliorate symptoms of idiopathic hyperhidrosis and associated conditions include 5-HT2C receptor antagonists (i.e., ketanserin, ritanserin, mianserin, mesulergine, cyproheptadine, fluoxetine, mirtazapine, olanzapine, and ziprasidone) as well as 5-HT2C receptor modulators (i.e., inverse agonists, partial agonists, and allosteric modulators).

Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing pulmonary arterial hypertension and/or stable angina. More particularly, aspects of the present invention are related to therapeutic combinations comprising a Rho-kinase inhibitor, such as fasudil, and one or more additional compounds selected from the group consisting of prostacyclins, such as iloprost, endothelin receptor antagonists, PDE inhibitors, calcium channel blockers, 5-HT_2A antagonists, such as sarpogrelate, selective serotonin reuptake inhibitors, such as fluoxetine, statins, and vascular remodeling modulators, such as Gleevec.

The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition. The lipophilic counterion may be a saturated or unsaturated C₈-C₂₂ fatty acid, and preferably may be a saturated or unsaturated C₁₀-C₁₈ fatty acid. The compounds precipitate in aqueous environments. When injected into a mammal, at least a portion of the composition precipitates and releases the active compound over time. Thus, the composition forms a slowly releasing drug depot of the active compound in the mammal. Therefore, the present invention enables one to provide a controlled dose administration of the active compound for a period of up to 15 days or even longer. Many compounds can be administered according to the present invention including, but not limited to, tilmicosin, oxytetracycline, metoprolol, fluoxetine, roxithromycin, and turbinafine.

The invention relates to application of tetrahydrocurcumin in preparing an antidepressant and a method for preparing a solid dispersion of the tetrahydrocurcumin. The invention aims to provide the application of the tetrahydrocurcumin to prepare the antidepressant. The tetrahydrocurcumin and a surfactant are mixed in certain proportion to obtain the solid dispersion of the tetrahydrocurcumin. The method for preparing the solid dispersion of the tetrahydrocurcumin comprises the following steps that: according to the weight ratio of 1:3-1:30, the tetrahydrocurcumin and the surfactant are heated until completely melted, frozen in a low-temperature environment, and taken out, dried and crushed to obtain the solid dispersion of the tetrahydrocurcumin. The tetrahydrocurcumin and the solid dispersion of the tetrahydrocurcumin are used for preparing drugs, health care products, foods or food additives of relieving mental depression. The tetrahydrocurcumin has the function of relieving mental depression, and the function of the tetrahydrocurcumin is possibly related with the influence on a monoamine neurotransmitter system; moreover, compared with fluoxetine, the tetrahydrocurcumin has the advantages of low toxicity and good curing effect.

The invention discloses a drug for treating depression. The drug contains an effective amount of 4-{4-(4-fluorophenyl)-1-[1-(isoxazole-3-ylmethyl)piperidine-4-yl]-1H-imidazole-5-yl}pyrimidine-2-amine and an effective amount of fluoxetine, and the mass ratio of 4-{4-(4-fluorophenyl)-1-[1-(isoxazole-3-ylmethyl)piperidine-4-yl]-1H-imidazole-5-yl}pyrimidine-2-amine to fluoxetine is 3:1 to 6:1. Through combined use of specific drugs, side effects during treatment of depression are greatly reduced, pain of patients is reduced, and recovery of the patients is availed.

The invention relates to a composite which is composed of (2Z, 8Z, 10E)-2,8,10-pentadecane triene-4,6-diyne-1-alcohol and (2Z, 8E, 10E)-2,8,10-pentadecane triene-4,6-diyne-1-alcohol according to the proportion of 1:(1-4) or is composed of (2Z, 8Z, 10E)-2,8,10-heptadecane triene-4,6-diyne-1-alcohol and (2Z, 8E, 10E)-2,8,10-heptadecane triene-4,6-diyne-1-alcohol according to the proportion of 1:(1-4). The composite disclosed by the invention is obtained by being extracted and separated from traditional Chinese medicine radix bupleuri. The result of an in-vitro monoamine neurotransmitter reuptake inhibition experiment shows that the composite disclosed by the invention has triple inhibition effects on the reuptake of 5-HT (5-Hydroxytryptamine), NA (noradrenalin) and DA (Dopamine), is higher than the effective part of ease powder petroleum ether and the part of radix bupleuri petroleum ether in inhibition ratio and is higher than positive control drugs, namely fluoxetine, norpramin and 6-hydroxydopamine, in inhibiting effect. According to the invention, two composites can be applied to prepare a drug used for preventing and curing depression.

Method for the treatment of psychiatric disorders, comprising administering to a subject in need thereof an amount of fatty acids and a suboptimal dose of at least one antidepressant. Wherein the fatty acid may be omega-3 (ω3), for example the docohexaenoic acid (DHA) and the eicosapentaenoic acid (EPA). The omega-3 fatty acid may be administered orally, in amounts that may be variable, for example in amounts between 0.15 and 1.00 g/kg/day. The antidepressant may be any antidepressant, preferably the antidepressant is fluoxetine or mirtazapine in sub-optimal doses.

The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition. The lipophilic counterion may be a saturated or unsaturated C₈-C₂₂ fatty acid, and preferably may be a saturated or unsaturated C₁₀-C₁₈ fatty acid. When injected into a mammal, at least a portion of the composition precipitates and releases the active compound over time. Thus, the composition forms a slowly releasing drug depot of the active compound in the mammal. Therefore, the present invention enables one to provide a controlled dose administration of the active compound for a periods of up to 15 days or even longer. Many compounds can be administered according to the present invention including, but not limited to, tilmicosin, oxytetracycline, metoprolol, fluoxetine, roxithromycin, and turbinafine.

The invention relates to a method for preparing antidepressant fluoxetine, and belongs to the method for preparing a medicinal compound. The technical scheme in the invention comprises the following three steps of aminolysis, catalytic hydrogenation and aromatic etherification reaction, wherein the three steps are performed in one pot without separation. In the method, the conventional chemical reduction method is replaced by the catalytic dehydration process, and the used reducing agent is hydrogen gas, so that the environmental pollution is reduced; the methylamine is gaseous methylamine, so that the reaction conversion rate is improved, and other substances, such as water and the like, are prevented from being introduced into a reaction system; and p-chlorobenzotrifluoride is added dropwise in the etherification reaction, so that the reaction speed can be conveniently controlled, the yield of a target product is improved, and the possibility of catalyst poisoning is reduced.

The invention relates to the technical field of medicines, and in particular to an application of andrographolide in preparing medicines for treating depression. Based upon researches with the assistance of various depression animal models and test methods, the andrographolide, through intraperitoneal injection, can obviously reverse various depression-like behaviors caused by the depression models, with efficacy intensity not weaker than that of a classical clinical anti-depression medicine, namely fluoxetine; therefore, as a completely new pharmacological effect, the andrographolide can be used for effectively relieving and treating the depression.

The invention discloses a method for producing (S)-3-chlorobenzene phenylpropanol through carbonyl reductase catalysis. The method is characterized by comprises the following steps: utilizing existingcarbonyl reductase as a catalyst; performing catalytic production on a substrate 3-chlorobenzene phenylpropanol to produce high-chirality ee (larger than 99) value (S)-fluoxetine intermediate (S)-3-chlorobenzene phenylpropanol; utilizing carbonyl reductase ChKRED20 as a catalyst, wherein a reaction system comprises a pH equal to 6.0 to 8.0, a 0.1M potassium phosphate buffer solution, the carbonylreductase ChKRED20, NADH (reduced coenzyme I) or NADPH (reduced coenzyme II) and the substrate. According to the method disclosed by the invention, a biological-enzyme catalytic method is utilized for preparing the high-chirality ee (larger than 99) value (S)-fluoxetine intermediate (S)-3-chlorobenzene phenylpropanol, a traditional chemical synthesizing method is replaced, and production cost andenvironmental pollution are reduced.

The present invention provides a pharmaceutical composition comprising a selective serotonin reuptake inhibitor (SSRI) and a norepinephrine reuptake inhibitor (NRI), particularly, fluoxetine and reboxetine, for treating obesity. Surprisingly, the inventor of the present invention discovered that use of especially low doses of the active compounds, particularly, at most 6 mg/day of reboxetine and at most 20 mg/day of fluoxetine, wherein the reboxetinerfluoxetine ratio is from about 1:4 to about 1:6, induces an effective weight loss in obese patients. Advantageously, the combinations of the present invention include very low doses of the active ingredients, thereby decreasing possible drug-drug interactions and adverse drug reaction.

Pharmaceutical formulations of fluoxetine or an acid addition salt thereof, suitable for manufacturing dispersible tablets by direct compression and comprising, in addition to the active ingredient, the appropriate excipients and coadjuvants, selected from among disintegrants, diluents, lubricants, anti-adherents, sweeteners, flavorings and, optionally, colorants. Said formulations are suitable for manufacturing dispersible tablets which disintegrate in less than three minutes in water at 19 DEG C - 21 DEG C, and are appropriate for treatment of depression.

The invention relates to an alcohol-soluble homogeneous polysaccharide and an anti-depression application thereof, in particular to a dendrobium officinale flower alcohol-soluble homogeneous polysaccharide, a preparation method thereof and an application of the dendrobium officinale flower alcohol-soluble homogeneous polysaccharide in preparation of an anti-depression drug. The alcohol-soluble homogeneous polysaccharide is obtained by purifying separated components of a natural plant aqueous extract for multiple times, and the alcohol-soluble homogeneous polysaccharide is named as ASP (Alcohol-soluble polysaccharide); and in-vivo experiments prove that the alcohol-soluble homogeneous polysaccharide has remarkable anti-depression activity, the action effect of the alcohol-soluble homogeneous polysaccharide is equivalent to that of fluoxetine serving as an anti-depression marketing drug, and the alcohol-soluble homogeneous polysaccharide can be further developed and prepared into the anti-depression drugs.

The invention relates to a drug compound for resisting against anxiety and improving sleep and an application thereof. The drug compound comprises the following active ingredients: tandospirone citrate, fluoxetine and sertraline hydrochloride. According to the invention, the tandospirone citrate, fluoxetine and sertraline hydrochloride are jointly used for treating anxiety disorder and insomnia, the defects of poor drug effect and easiness in generating drug dependence of the patient of single drug usage are overcome, the joint use of three drugs has the synergic effects of resisting against anxiety and improving sleep and the function of reducing toxicity can be achieved in the manner of reducing the clinical dosage of one or two drugs.